AbCellera Biologics (ABCL) Insider Trading & Ownership $4.26 +0.02 (+0.35%) As of 02:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AbCellera Biologics (NASDAQ:ABCL) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage28.90%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$4.25MNumber OfInsiders Selling(Last 3 Years)0 Get ABCL Insider Trade Alerts Want to know when executives and insiders are buying or selling AbCellera Biologics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ABCL Insider Buying and Selling by Quarter AbCellera Biologics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/26/2023Andrew BoothCFOBuy14,500$6.85$99,325.00 5/26/2023Holdings Ltd. ThermopylaeMajor ShareholderBuy153,000$6.52$997,560.00 12/16/2022Holdings Ltd. ThermopylaeMajor ShareholderBuy85,102$10.10$859,530.20 8/19/2022Holdings Ltd. ThermopylaeMajor ShareholderBuy200,000$11.46$2,292,000.00 (Data available from 1/1/2013 forward) ABCL Insider Trading Activity - Frequently Asked Questions Who is on AbCellera Biologics' Insider Roster? The list of insiders at AbCellera Biologics includes Andrew Booth, and Holdings Ltd. Thermopylae. Learn more on insiders at ABCL. What percentage of AbCellera Biologics stock is owned by insiders? 28.90% of AbCellera Biologics stock is owned by insiders. Learn more on ABCL's insider holdings. AbCellera Biologics Key ExecutivesDr. Carl L.G. Hansen Ph.D. (Age 49)CEO, President & Chairperson Compensation: $714.94kMr. Andrew Booth M.B.A. (Age 50)Chief Financial Officer Compensation: $674.55kDr. Veronique Lecault Ph.D. (Age 39)COO & Director Compensation: $650.59kMr. Tryn T. Stimart Esq. (Age 54)J.D., M.Sc., Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Compensation: $667.69kMarcie Thiessen CPACGA, Senior Director of Finance & AccountingDr. Ester Falconer Ph.D. (Age 49)Chief Technology Officer Kathleen Reid B.A.Head of Corporate CommunicationsGraham Craig M.Sc.Director of Corporate DevelopmentMr. Murray McCutcheon Ph.D.Senior Vice President of PartneringMr. Neil Aubuchon B.A. (Age 54)M.B.A., Chief Commercial Officer Compensation: $684.81k More Insider Trading Tools from MarketBeat Related Companies CRSP Insider Ownership LNTH Insider Ownership ADMA Insider Ownership MRUS Insider Ownership TGTX Insider Ownership RNA Insider Ownership CYTK Insider Ownership PCVX Insider Ownership ZLAB Insider Ownership PTCT Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:ABCL) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
